Press Releases

Health News Posted on Sunday, September 22, 2019

Press Releases »

Adalbert Czerny Award 2019 goes to Dr. med. Ferdinand Knieling for his work on using MSOT for diagnosis of Inflammatory Bowel Disease and Muscular Dystrophy

Dr. Ferdinand Knieling from the University Hospital Erlangen was awarded the Adalbert Czerny Award 2019 from the German Society for Pediatrics and Youth Medicine (DGKJ) for his work on innovative diagnostic methods. He was the first to apply a ...

Read More

Innovation in Emergency Room Care is Noted on an Episode of "Behind The Scenes" with Laurence Fishburne

An upcoming episode of the program will highlight changes in the way Emergency Rooms operate. MIAMI , Sept. 22, 2019 /PRNewswire-PRWeb/ -- Noted actor Laurence Fishburne is using his performance skills and gravitas for informative purposes ...

Read More

The Baldwin County Community Alliance will unveil its newest tool to fight prescription drug abuse

The misuse of and addiction to opioids--including prescription pain relievers, is a national crisis that affects public health as well as social and economic welfare. The incinerator is another tool to decrease the misuse of opioids by properly ...

Read More

Leading Bellevue Medspa A-to-Zen Cosmetic Surgery & Aesthetics Expands Menu With SkinPen® Microneedling in Bellevue, WA

A-to-Zen Cosmetic Surgery & Aesthetics, a leading medical spa in Bellevue, WA, has added SkinPen® microneedling to its leading menu of cosmetic treatments. BELLEVUE, Wash. , Sept. 22, 2019 /PRNewswire-PRWeb/ -- A-to-Zen Cosmetic Surgery ...

Read More

2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors

SUZHOU, China , Sept. 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced results from the microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumor cohort in the ...

Read More

2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab

SUZHOU, China , Sept. 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced preliminary results from the Phase Ia trial of the Company's anti-CTLA-4 antibody in an oral presentation at the 22nd ...

Read More
More Press Releases

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.